# Rademikibart IV for Acute Asthma and COPD Exacerbation

> **NCT07705737** · PHASE2 · RECRUITING · sponsor: **Connect Biopharm LLC** · enrollment: 40 (estimated)

## Conditions studied

- Asthma Acute
- COPD Exacerbation Acute

## Interventions

- **DRUG:** Rademikibart

## Key facts

- **NCT ID:** NCT07705737
- **Lead sponsor:** Connect Biopharm LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-08-21
- **Primary completion:** 2026-12
- **Final completion:** 2027-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-08-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07705737

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07705737, "Rademikibart IV for Acute Asthma and COPD Exacerbation". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07705737. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*